Market Cap
₹102 Cr.
P/E
529.74
Quick View
  • 1d
  • 1m
  • 6m
  • YTD
  • 1y
  • 3y
  • 5y
  • 10y
  • max

Company Timeline

Forensics

8 Yes

Positive for this company

1 Neutral

Neutral for this company

7 No

Negative for this company

1 No Data

Insufficient data to analyse

ROE
Latest
-0.39%
3yr Average
10.5%
5yr Average
18.45%
Net Profit Margin
Latest
-0.1%
3yr Average
2.68%
5yr Average
3.87%
ROCE
Latest
5.29%
3yr Average
16.03%
5yr Average
25.78%
Debt to Equity
Latest
1.1
3yr Average
0.81
5yr Average
0.75
Revenue mix

Product Wise Break-Up

locked
Source
|
Latest
|
locked
Historic

Segment Break-Up

locked
Source
|
Latest
|
locked
Historic

Location Wise Break-Up

locked
Source
|
Latest
|
locked
Historic

Raw Material Break-Up

locked
Source
|
Latest
|
locked
Historic
Show more
Operational Metrics

    Select a Metric
    • Manufacturing Capacity - Esomeprazole (MTPA)
    • Capacity Utilization - Esomeprazole (%)
    • Capacity Utilization - Benzimidazole (%)
    • Capacity Utilization - Omeprazole (%)
    • Realization - Pantaprazole Sodium (Rs/Tonne)
    • Realization - Ammonium Sulphate (Rs/Tonne)
    • Realization - Esomeprazole Magnesium (Rs/Tonne)
    • Realization - Chloro Compound (Rs/Tonne)
    • Manufacturing Capacity - Pantaprazole (MTPA)
    • Realization - Omeprazole Powder (Rs/Tonne)
    • Manufacturing Capacity - Benzimidazole (MTPA)
    • Capacity Utilization - Chloro Compound (%)
    • Realization - Benzimidazole (Rs/Tonne)
    • Realization - Op. Sulphide (Rs/Tonne)
    • Capacity Utilization - Pantaprazole (%)
    • Manufacturing Capacity - Chloro Compound (MTPA)
    • Realization - Tetralone (Rs/Tonne)
    • Manufacturing Capacity - Omeprazole (MTPA)
    • R&D as a % of Total Sales (%)
    Peer Comparison
    Company Filing
    Show Previous Years
    Discussions & Analysis